Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: A review paper

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 8-15

  Breitscheidel, L ^a   Stamenitis, S ^a   Dippel, F W ^b   Schoffski O ^c  

^a Kendle GmbH   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adherence; Compliance; Costs; Persistence; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; GLITAZONE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MEDICAL LITERATURE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REIMBURSEMENT; REVIEW;

ALGORITHMS; DEPRESSION; DIABETES MELLITUS, TYPE 2; GERMANY; HEALTH CARE COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; MODELS, ECONOMIC;

EID: 77149180147     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903479199     Document Type: Review

References (31)

1. Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res 2005;36:300-306
2. Revicki D, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423-434
3. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47
4. Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498-509
5. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932
6. Menzin J, Langley-Hawthorne C, Friedman M, et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24:51-55
7. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-189
8. Salas M, Hughes D, Zuluaga A, et al. Costs of medication non-adherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009;12:915-922
9. Lee W, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41
10. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36
11. Shenolikar RA, Balkrishnan R. Oral antidiabetes medication adherence and health care utilisation among Medicaid-enrolled type 2 diabetic patients beginning monotherapy. Diabetes Care 2008;31(2):e5
12. Pawaskar M, Camacho F, Anderson R, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294-1305
13. Shenolikar R, Balkrishnan R, Camacho F, et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006;28:1199-1207
14. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-962
15. Karve S, Cleves M, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-1133
16. Balkrishnan R, Rajagopalan R, Shenolikar RA, et al. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. Curr Med Res Opin 2006;22:551-559
17. Sokol M, McGuigan K, Verbrugge R, Epstein R. Impact of medication adherence on hospitalisation risk and healthcare cost. Med Care 2005;43:521-530
18. Hepke K, Martus M, Share D. Costs and utilisation associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-151
19. Balkrishnan R, Rajagopalan R, Camacho F, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-2971
20. Cherry J, Moffatt T, Rodriguez C, Dryden K. Diabetes disease management program for an indigent population empowered by telemedicine technology. Diabetes Technol Ther 2002;4:783-791
21. Ciechanowski P, Katon W, Russo J. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-3285
22. Lee W, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725
23. Steiner J, Koepsell T, Fihn S, Inui T. A general method of compliance assessment using centralized pharmacy records. Med Care 1988;26:814-823
24. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
25. Clark D, von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783-795
26. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-387
27. Ellis RP, Ash A. Refinements to the Diagnostic Cost Group (DCG) model. Inquiry 1995-1996;32(4):418-429
28. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycaemic control on managed care organizations: a review of the literature. Manag Care Pharm 2006;12:130-142
29. Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes 2005;29:186-192
30. Amiel S, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-254
31. Falagas ME, Pitsouni EI, Malietzis GA. Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J 2008;22:338-342